Amycretin Dual-Agonist Peptide Reports Positive Phase 2 Weight Loss Data
Novo Nordisk's amycretin, a novel GLP-1/amylin dual-agonist peptide, demonstrates impressive weight loss results in phase 2 trial, potentially rivaling current leading therapies.
Novo Nordisk has released positive phase 2 results for amycretin, a novel peptide that combines GLP-1 and amylin receptor agonist activity in a single molecule. The dual-agonist approach achieved weight loss of approximately 13% over 12 weeks, a trajectory that could potentially match or exceed current leading obesity medications over longer treatment durations.
What We Know
The phase 2 trial enrolled 125 participants with obesity or overweight with at least one weight-related comorbidity. Participants were randomized to receive escalating doses of amycretin or placebo, administered via once-weekly subcutaneous injection. The primary endpoint was percent change in body weight at 12 weeks [amycretin-phase2-data].
Participants receiving the highest dose of amycretin achieved mean weight loss of 13.1% at 12 weeks, with weight loss curves showing no plateau, suggesting additional efficacy with continued treatment. By comparison, semaglutide typically produces approximately 6-7% weight loss at 12 weeks en route to its eventual 15% reduction.
The mechanism of amycretin differs from existing approved medications. While semaglutide acts solely on GLP-1 receptors and tirzepatide targets both GLP-1 and GIP receptors, amycretin combines GLP-1 activity with amylin receptor agonism, creating a complementary approach to appetite regulation [novo-nordisk-announcement].
The Amylin Mechanism
Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells that contributes to satiety and slows gastric emptying. Pramlintide, a synthetic amylin analog, has been available for diabetes treatment but requires multiple daily injections and produces modest weight loss when used alone.
The innovation of amycretin lies in uniting amylin and GLP-1 activity in a single molecule optimized for once-weekly dosing. This approach may provide synergistic effects beyond what either mechanism achieves independently [amylin-mechanism-review].
Amylin acts primarily in the area postrema and other brainstem regions to promote satiety, while GLP-1 works through both peripheral and central mechanisms. The combination potentially provides more comprehensive appetite control than single-mechanism approaches.
What It Means
The results position amycretin as a serious contender in the increasingly competitive obesity medication landscape. Novo Nordisk, which currently leads the market with semaglutide products, is developing multiple next-generation candidates to maintain its position against competition from Eli Lilly and others.
The trajectory of weight loss at 12 weeks suggests amycretin could potentially achieve 20-25% or greater total body weight reduction over a full treatment course, which would be competitive with retatrutide and other advanced candidates.
For patients, the proliferation of highly effective obesity medications offers hope for matching individual physiology with optimal treatment. Different mechanisms may prove more effective for different patient populations, moving the field toward more personalized approaches.
The gastrointestinal tolerability profile will be critical for amycretin’s commercial success. Nausea, vomiting, and other GI side effects are the primary reason patients discontinue GLP-1 medications. Phase 2 data suggested acceptable tolerability, but larger trials will provide more definitive safety information.
What’s Next
Novo Nordisk has announced plans to advance amycretin into phase 3 development, with pivotal trials expected to begin in 2026. The company aims to develop the medication for both obesity and type 2 diabetes indications.
Longer-term data from ongoing extension studies will clarify the magnitude of weight loss achievable with continued treatment and assess durability of effect. Cardiovascular outcomes data, now expected for any major obesity medication, will eventually be required.
The competitive dynamics in obesity drug development continue to intensify. Eli Lilly’s retatrutide, Novo’s own cagrilintide-semaglutide combination, and numerous other candidates are all progressing through clinical development, promising patients a robust pipeline of options in coming years.
Manufacturing and supply chain considerations will also factor into amycretin’s development. The GLP-1 medication class has faced significant supply constraints, and Novo Nordisk is investing heavily in production capacity expansion.
This information is provided for educational purposes only and does not constitute medical advice.
Sources & Citations
- 1
- 2
- 3
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.